Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
Rhea-AI Summary
Calidi Biotherapeutics (NYSE American: CLDI) reported that it presented new data on July 23, 2026, at the AACR Drug Discovery and Development Conference in Boston. The presentation covered cytotoxicity and IL-15 SA expression data from its CLD-401 program, which Calidi expects to enter the clinic in the first quarter of 2027, and its in situ T-cell engager (TCE) program, including a new TCE targeting the EpCam receptor.
According to Calidi, CLD-401 is the lead candidate from its RedTail platform, currently in IND-enabling studies for metastatic non-small cell lung cancer, head and neck cancer, and other tumors. The RedTail platform uses an engineered enveloped oncolytic virus designed for systemic delivery to metastatic sites.
Positive
- None.
Negative
- None.
Market reaction after CLD-401 clinical data: CLDI +9.50% in the Jul 27 session
In the Jul 27 session, CLDI gained 9.50%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.5% during that session. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Corporate update | Positive | -13.9% | Regulatory, pipeline, governance, and cost-cutting progress highlighted in mid-year update |
| Jul 20 | Reverse split | Negative | -13.9% | Company announced a 1-for-16 reverse stock split effective July 31 |
| Jul 08 | Inducement grant | Negative | +5.3% | Company granted a 100,000-share stock option to its new finance executive |
| Jun 24 | TCE data | Positive | +0.6% | Company presented CLD-501 proof-of-concept data targeting the TROP2 receptor |
| Jun 23 | Board appointment | Positive | -2.5% | Biopharma veteran Corsee Sanders joined the independent board effective June 17 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock diverged from the apparent announcement sentiment in three of five recent events and aligned in two.
Key Terms
cytotoxicity medical
il-15 sa medical
in situ t-cell engager medical
epcam receptor medical
ind-enabling studies regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on July 23, 2026, at the American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference in Boston, MA. The Company presented new data on its CLD-401 program that it expects to enter the clinic in the first quarter of 2027 and its in situ T-cell engager (TCE) program.
“The data presented last week at the conference shows the advances we have made in both our CLD-401 program that we expect will be entering the clinic soon and our in situ TCE program including a new TCE targeting the EpCam receptor,” said Calidi Chief Executive Officer Eric Poma, PhD. “The data highlights the unique ability of the RedTail platform to deliver genetic medicines to distal tumor sites to drive efficacy.”
About Calidi
Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.
CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For Investors:
For Media:
